GlassScriptPhysician profile
Salvador E Murra
NPI 1962481838
$5,312.94
in general payments reported to CMS, 2019-2025
42 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $1,135 · 2021: $1,047 · 2022: $1,087 · 2023: $371 · 2024: $614 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.58 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $828.21 | 2020-2025 | Valtoco |
| Ucb, INC. | $700.76 | 2019-2022 | |
| Eisai INC. | $417.17 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $395.63 | 2019-2022 | |
| Emd Serono, INC. | $281.19 | 2020-2022 | |
| Aquestive Therapeutics, INC. | $261.77 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $227.44 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $221.03 | 2019-2022 | |
| Sk Life Science, INC. | $211.32 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $202.16 | 2019-2025 | Crexont |
| Abbvie INC. | $157.14 | 2020-2022 | |
| Allergan, INC. | $122.61 | 2020 | |
| Genzyme Corporation | $111.56 | 2019-2022 | |
| Genentech USA, INC. | $94.55 | 2020-2025 | Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $91.18 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvador Murra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.